Article
Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2018
Serra Pierre, Petat Arthur, Maury Jean-Michel, Thivolet-Bejui Françoise, Chalabreysse Lara, Barritault Marc, Ebran Nathalie, Milano Gérard, Girard Nicolas, Brevet Marie
Abstract excerpt
INTRODUCTION: The systematic assessment of anti-programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) in lung adenocarcinomas is becoming standard practice. However, the assessment of PD-L1 expression on small tissue specimens needs to be evaluated and the association with other features more thoroughly analyzed. METHODS: This retrospective single center study evaluated the...
Topics
Join the communities discussing this publication.
